Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Randomized investigation of increased dialyzer membrane hydrophilicity on hemocompatibility and performance

G. Ehlerding, W. Ries, M. Kempkes-Koch, E. Ziegler, P. Ronová, M. Krizsán, J. Verešová, M. Böke, A. Erlenkötter, R. Nitschel, AM. Zawada, JP. Kennedy, J. Braun, JW. Larkin, N. Korolev, T. Lang, B. Ottillinger, M. Stauss-Grabo, B. Griesshaber

. 2024 ; 25 (1) : 220. [pub] 20240710

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, randomizované kontrolované studie, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc24019764

BACKGROUND: Hemodialyzers should efficiently eliminate small and middle molecular uremic toxins and possess exceptional hemocompatibility to improve well-being of patients with end-stage kidney disease. However, performance and hemocompatibility get compromised during treatment due to adsorption of plasma proteins to the dialyzer membrane. Increased membrane hydrophilicity reduces protein adsorption to the membrane and was implemented in the novel FX CorAL dialyzer. The present randomized controlled trial compares performance and hemocompatibility profiles of the FX CorAL dialyzer to other commonly used dialyzers applied in hemodiafiltration treatments. METHODS: This prospective, open, controlled, multicentric, interventional, crossover study randomized stable patients on post-dilution online hemodiafiltration (HDF) to FX CorAL 600, FX CorDiax 600 (both Fresenius Medical Care) and xevonta Hi 15 (B. Braun) each for 4 weeks. Primary outcome was β2-microglobulin removal rate (β2-m RR). Non-inferiority and superiority of FX CorAL versus comparators were tested. Secondary endpoints were RR and/or clearance of small and middle molecules, and intra- and interdialytic profiles of hemocompatibility markers, with regards to complement activation, cell activation/inflammation, platelet activation and oxidative stress. Further endpoints were patient reported outcomes (PROs) and clinical safety. RESULTS: 82 patients were included and 76 analyzed as intention-to-treat (ITT) population. FX CorAL showed the highest β2-m RR (76.28%), followed by FX CorDiax (75.69%) and xevonta (74.48%). Non-inferiority to both comparators and superiority to xevonta were statistically significant. Secondary endpoints related to middle molecules corroborated these results; performance for small molecules was comparable between dialyzers. Regarding intradialytic hemocompatibility, FX CorAL showed lower complement, white blood cell, and platelet activation. There were no differences in interdialytic hemocompatibility, PROs, or clinical safety. CONCLUSIONS: The novel FX CorAL with increased membrane hydrophilicity showed strong performance and a favorable hemocompatibility profile as compared to other commonly used dialyzers in clinical practice. Further long-term investigations should examine whether the benefits of FX CorAL will translate into improved cardiovascular and mortality endpoints. TRIAL REGISTRATION: eMPORA III registration on 19/01/2021 at ClinicalTrials.gov (NCT04714281).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24019764
003      
CZ-PrNML
005      
20241024111008.0
007      
ta
008      
241015s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12882-024-03644-5 $2 doi
035    __
$a (PubMed)38987671
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Ehlerding, Götz $u Zentrum für Nieren-, Hochdruck- und Stoffwechselerkrankungen, 30453, Hannover, Germany
245    10
$a Randomized investigation of increased dialyzer membrane hydrophilicity on hemocompatibility and performance / $c G. Ehlerding, W. Ries, M. Kempkes-Koch, E. Ziegler, P. Ronová, M. Krizsán, J. Verešová, M. Böke, A. Erlenkötter, R. Nitschel, AM. Zawada, JP. Kennedy, J. Braun, JW. Larkin, N. Korolev, T. Lang, B. Ottillinger, M. Stauss-Grabo, B. Griesshaber
520    9_
$a BACKGROUND: Hemodialyzers should efficiently eliminate small and middle molecular uremic toxins and possess exceptional hemocompatibility to improve well-being of patients with end-stage kidney disease. However, performance and hemocompatibility get compromised during treatment due to adsorption of plasma proteins to the dialyzer membrane. Increased membrane hydrophilicity reduces protein adsorption to the membrane and was implemented in the novel FX CorAL dialyzer. The present randomized controlled trial compares performance and hemocompatibility profiles of the FX CorAL dialyzer to other commonly used dialyzers applied in hemodiafiltration treatments. METHODS: This prospective, open, controlled, multicentric, interventional, crossover study randomized stable patients on post-dilution online hemodiafiltration (HDF) to FX CorAL 600, FX CorDiax 600 (both Fresenius Medical Care) and xevonta Hi 15 (B. Braun) each for 4 weeks. Primary outcome was β2-microglobulin removal rate (β2-m RR). Non-inferiority and superiority of FX CorAL versus comparators were tested. Secondary endpoints were RR and/or clearance of small and middle molecules, and intra- and interdialytic profiles of hemocompatibility markers, with regards to complement activation, cell activation/inflammation, platelet activation and oxidative stress. Further endpoints were patient reported outcomes (PROs) and clinical safety. RESULTS: 82 patients were included and 76 analyzed as intention-to-treat (ITT) population. FX CorAL showed the highest β2-m RR (76.28%), followed by FX CorDiax (75.69%) and xevonta (74.48%). Non-inferiority to both comparators and superiority to xevonta were statistically significant. Secondary endpoints related to middle molecules corroborated these results; performance for small molecules was comparable between dialyzers. Regarding intradialytic hemocompatibility, FX CorAL showed lower complement, white blood cell, and platelet activation. There were no differences in interdialytic hemocompatibility, PROs, or clinical safety. CONCLUSIONS: The novel FX CorAL with increased membrane hydrophilicity showed strong performance and a favorable hemocompatibility profile as compared to other commonly used dialyzers in clinical practice. Further long-term investigations should examine whether the benefits of FX CorAL will translate into improved cardiovascular and mortality endpoints. TRIAL REGISTRATION: eMPORA III registration on 19/01/2021 at ClinicalTrials.gov (NCT04714281).
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    12
$a membrány umělé $7 D008567
650    12
$a klinické křížové studie $7 D018592
650    _2
$a senioři $7 D000368
650    12
$a hemodiafiltrace $x přístrojové vybavení $x metody $7 D017583
650    12
$a hydrofobní a hydrofilní interakce $7 D057927
650    _2
$a prospektivní studie $7 D011446
650    _2
$a beta-2-mikroglobulin $x krev $7 D001613
650    _2
$a chronické selhání ledvin $x terapie $7 D007676
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Ries, Wolfgang $u Diakonissenkrankenhaus, Innere Medizin, Abtlg. Nephrologie, 24939, Flensburg, Germany
700    1_
$a Kempkes-Koch, Manuela $u PHV-Dialysezentrum Goslar, 38642, Goslar, Germany
700    1_
$a Ziegler, Ekkehard $u Nieren- und Gefäßzentrum Kiel, 24106, Kiel, Germany
700    1_
$a Ronová, Petra $u Fresenius Nephrocare Praha 9, Praha, 19061, Czechia
700    1_
$a Krizsán, Mária $u Péterfy II. Dialízis Központ, Budapest, 1077, Hungary
700    1_
$a Verešová, Jana $u Fresenius Nephrocare Nymburk, Nymburk, 28802, Czechia
700    1_
$a Böke, Mária $u Váci Dialízis Központ, Vác, 2600, Hungary
700    1_
$a Erlenkötter, Ansgar $u Fresenius Medical Care Deutschland GmbH, Biosciences, VS Dialyzers, Care Enablement, 66606, St. Wendel, Germany
700    1_
$a Nitschel, Robert $u Fresenius Medical Care Deutschland GmbH, Biosciences, VS Dialyzers, Care Enablement, 66606, St. Wendel, Germany
700    1_
$a Zawada, Adam M $u Fresenius Medical Care Deutschland GmbH, Product Development, VS Dialyzers, Care Enablement, 66606, St. Wendel, Germany
700    1_
$a Kennedy, James P $u Fresenius Medical Care Deutschland GmbH, Product Development, VS Dialyzers, Care Enablement, 66606, St. Wendel, Germany
700    1_
$a Braun, Jennifer $u Fresenius Medical Care Deutschland GmbH, Global Biomedical Evidence Generation, Global Medical Office, 61352, Bad Homburg, Germany
700    1_
$a Larkin, John W $u Fresenius Medical Care, Global Medical Office, Waltham, MA, USA
700    1_
$a Korolev, Natalia $u Fresenius Medical Care Deutschland GmbH, Global Biomedical Evidence Generation, Global Medical Office, 61352, Bad Homburg, Germany
700    1_
$a Lang, Thomas $u Fresenius Medical Care Deutschland GmbH, Global Biomedical Evidence Generation, Global Medical Office, 61352, Bad Homburg, Germany
700    1_
$a Ottillinger, Bertram $u Ottillinger Life Sciences, 85649, Brunnthal, Germany
700    1_
$a Stauss-Grabo, Manuela $u Fresenius Medical Care Deutschland GmbH, Global Biomedical Evidence Generation, Global Medical Office, 61352, Bad Homburg, Germany
700    1_
$a Griesshaber, Bettina $u Fresenius Medical Care Deutschland GmbH, Global Biomedical Evidence Generation, Global Medical Office, 61352, Bad Homburg, Germany. Bettina.Griesshaber@freseniusmedicalcare.com
773    0_
$w MED00008194 $t BMC nephrology $x 1471-2369 $g Roč. 25, č. 1 (2024), s. 220
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38987671 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024111002 $b ABA008
999    __
$a ok $b bmc $g 2202158 $s 1231737
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 25 $c 1 $d 220 $e 20240710 $i 1471-2369 $m BMC nephrology $n BMC Nephrol $x MED00008194
LZP    __
$a Pubmed-20241015

Najít záznam

Citační ukazatele

Možnosti archivace